Vimarsana
Biggest News Aggregation in the World

Jonathan Barratt News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Jonathan Barratt. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Jonathan Barratt Today - Breaking & Trending Today

BLOOMBERG Bloomberg Daybreak Asia July 14, 2024 - Vimarsana News

BLOOMBERG Bloomberg Daybreak Asia July 14, 2024

Worries about growth and demand are outweighing the lift from opecs cuts. Samsung reports earnings that seem sluggish domestic data and export curbs from japan. Shery happy fourth of july. U. S. Equity and bond markets closed on this Independence Day holiday. Lets see how things are shaping up for asian markets. Sophie while our american friends are enjoying their july 4, futures are heading higher ahead of the jobs report due friday, with s p futures topping 3000 early. Ian stocks set for him a mixed end. In australia, we will be gauging reaction to the government devoting income tax relief t...

Jonathan Barratt, MD: Matching-Adjusted Indirect Comparisons of eGFR slopes for IgAN Treatments - Vimarsana News

Jonathan Barratt, MD: Matching-Adjusted Indirect Comparisons of eGFR slopes for IgAN Treatments

Jonathan Barratt, MD, discusses a matching-adjusted indirect comparison of sparsentan and irbesartan against standard of care plus optimized RASI.

Zigakibart 52-Week Data Demonstrate Potential in IgA Nephropathy - Vimarsana News

Zigakibart 52-Week Data Demonstrate Potential in IgA Nephropathy

Jonathan Barratt, MD, discusses the 52-week data from the phase 1/2 trial of zigakibart, which was presented at the 61st European Renal Association Congress.

In-Person & Virtual R&D Day: The Anti-Fibrotic Effects of Setanaxib and TARPEYO's Mode of Action - Vimarsana News

In-Person & Virtual R&D Day: The Anti-Fibrotic Effects of Setanaxib and TARPEYO's Mode of Action

/PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Calliditas") today announced that it will hold an in-person and virtual...

Calliditas Therapeutics: In-Person & Virtual R&D Day: The Anti-Fibrotic Effects of Setanaxib and TARPEYO's Mode of Action - Vimarsana News

Calliditas Therapeutics: In-Person & Virtual R&D Day: The Anti-Fibrotic Effects of Setanaxib and TARPEYO's Mode of Action

STOCKHOLM, May 16, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Calliditas") today announced that it will hold an in-person and virtual R&D day